Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for colorectal cancer (CRC) in patients with type 2 diabetes, with and without overweight or obesity, according ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback